Madrigal Pharmaceuticals Inc (MDGL)

$474.28 +2.96 (0.63%)
Market Cap 11.00B
Revenue (ttm) 958.40M
Net Income (ttm) -288.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -30.08%
Debt to Equity Ratio 0.63
Volume 278,705
Avg Vol 289,562
Day's Range N/A - N/A
Shares Out 23.06M
Stochastic %K 35%
Beta -1.07
Analysts Strong Sell
Price Target $672.56

Company Profile

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 267 824 2827
Address:
Four Tower Bridge, 200 Barr Harbor Drive Suite 200, West Conshohocken, United States
Wallst45
Wallst45 Jun. 11 at 7:27 PM
$MDGL again sell off into close lol 😂
0 · Reply
Wallst45
Wallst45 Jun. 11 at 5:51 PM
$MDGL may be Madrigal signed NDA with the buyer ??
0 · Reply
Wallst45
Wallst45 Jun. 11 at 5:27 PM
$MDGL silent buyout announcement only ?
0 · Reply
sarkar20
sarkar20 Jun. 11 at 4:27 PM
$MDGL What is happening? Why Madrigal is not releasing good news!! 🤔🤔 I found below great news and it is not released or have not seen by me. So they are going into Middle east region too!! 🔥🔥
0 · Reply
Wallst45
Wallst45 Jun. 11 at 1:50 PM
$MDGL makes sense
0 · Reply
Wallst45
Wallst45 Jun. 11 at 12:47 PM
$MDGL looks like they are hanging in the price as talks continue ??
1 · Reply
Live2ride
Live2ride Jun. 11 at 11:55 AM
$MDGL Hope we catch a bid today. We are due.
0 · Reply
Wallst45
Wallst45 Jun. 10 at 6:01 PM
$MDGL volumes picking up today, what’s brewing??
1 · Reply
Live2ride
Live2ride Jun. 10 at 5:57 PM
$MDGL Can we get back to a 5 handle please?
0 · Reply
Wallst45
Wallst45 Jun. 10 at 4:24 PM
$MDGL going to be very profitable and no more BD, nice 👍🏼
0 · Reply
Latest News on MDGL
Madrigal Pharmaceuticals price target lowered to $542 from $550 at BofA

2026-06-11T10:41:26.000Z - 10 hours ago

Madrigal Pharmaceuticals price target lowered to $542 from $550 at BofA

Madrigal Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 10, 2026, 11:20 AM EDT - 1 day ago

Madrigal Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Jun 4, 2026, 4:05 PM EDT - 7 days ago

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

Jun 3, 2026, 8:00 AM EDT - 8 days ago

Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

Madrigal Pharmaceuticals announces new analyses of Rezdiffra data

2026-05-27T14:23:26.000Z - 15 days ago

Madrigal Pharmaceuticals announces new analyses of Rezdiffra data

Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

May 27, 2026, 8:00 AM EDT - 15 days ago

Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

May 20, 2026, 8:00 AM EDT - 22 days ago

Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist

2026-05-13T13:52:07.000Z - 4 weeks ago

Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist

Madrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord

2026-05-07T16:42:06.000Z - 5 weeks ago

Madrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord

Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI

2026-05-07T13:49:17.000Z - 5 weeks ago

Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI

Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)

2026-05-07T07:31:11.000Z - 5 weeks ago

Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)

Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street

2026-05-07T00:53:12.000Z - 5 weeks ago

Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street

Madrigal Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 5 weeks ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q1 2026

Madrigal Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 8:00 AM EDT - 5 weeks ago

Madrigal Pharmaceuticals Earnings release: Q1 2026

Madrigal Pharmaceuticals Slides: Q1 2026

May 6, 2026, 8:00 AM EDT - 5 weeks ago

Madrigal Pharmaceuticals Slides: Q1 2026

Madrigal Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 8:00 AM EDT - 5 weeks ago

Madrigal Pharmaceuticals Quarterly report: Q1 2026

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

May 6, 2026, 7:00 AM EDT - 5 weeks ago

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma

2026-05-05T12:17:38.000Z - 5 weeks ago

Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma

ARWR

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

May 5, 2026, 8:00 AM EDT - 5 weeks ago

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

May 5, 2026, 8:00 AM EDT - 5 weeks ago

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

ARWR

Madrigal Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 6 weeks ago

Madrigal Pharmaceuticals Proxy statement: Proxy filing

Madrigal Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 6 weeks ago

Madrigal Pharmaceuticals Proxy statement: Proxy filing

Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026

Apr 22, 2026, 8:00 AM EDT - 7 weeks ago

Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026

Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading

2026-03-26T19:00:15.000Z - 2 months ago

Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading

Madrigal Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 2:30 PM EST - 3 months ago

Madrigal Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 3 months ago

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA

2026-02-20T12:26:01.000Z - 3 months ago

Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA

Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 19, 2026, 8:00 AM EST - 4 months ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2025

Madrigal Pharmaceuticals Annual report: Q4 2025

Feb 19, 2026, 8:00 AM EST - 4 months ago

Madrigal Pharmaceuticals Annual report: Q4 2025

Madrigal Pharmaceuticals Earnings release: Q4 2025

Feb 19, 2026, 8:00 AM EST - 4 months ago

Madrigal Pharmaceuticals Earnings release: Q4 2025

Madrigal Pharmaceuticals Slides: Q4 2025

Feb 19, 2026, 8:00 AM EST - 4 months ago

Madrigal Pharmaceuticals Slides: Q4 2025

Madrigal Pharmaceuticals reports Q4 EPS ($2.57), consensus (88c)

2026-02-19T12:08:24.000Z - 4 months ago

Madrigal Pharmaceuticals reports Q4 EPS ($2.57), consensus (88c)

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

Feb 19, 2026, 7:00 AM EST - 4 months ago

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

Feb 11, 2026, 6:25 AM EST - 4 months ago

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

Madrigal Pharmaceuticals announces exclusive license pact with Suzho Ribo

2026-02-11T10:10:18.000Z - 4 months ago

Madrigal Pharmaceuticals announces exclusive license pact with Suzho Ribo

Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs

Feb 11, 2026, 5:00 AM EST - 4 months ago

Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs

Madrigal Pharmaceuticals price target lowered to $570 from $595 at BofA

2026-02-03T11:50:48.000Z - 4 months ago

Madrigal Pharmaceuticals price target lowered to $570 from $595 at BofA

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026

Feb 2, 2026, 8:05 AM EST - 4 months ago

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026

Madrigal Pharmaceuticals initiated with an Overweight at Barclays

2026-01-27T21:31:28.000Z - 4 months ago

Madrigal Pharmaceuticals initiated with an Overweight at Barclays

Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)

Jan 21, 2026, 4:05 PM EST - 5 months ago

Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals price target raised to $745 from $527 at Citizens

2026-01-20T10:55:09.000Z - 5 months ago

Madrigal Pharmaceuticals price target raised to $745 from $527 at Citizens

Madrigal Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 5 months ago

Madrigal Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Madrigal Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 5 months ago

Madrigal Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Madrigal Pharmaceuticals price target raised to $644 from $554 at TD Cowen

2026-01-12T13:47:51.000Z - 5 months ago

Madrigal Pharmaceuticals price target raised to $644 from $554 at TD Cowen

PFE

Madrigal Pharmaceuticals expands MASH pipeline with global license agreement

2026-01-09T13:10:25.000Z - 5 months ago

Madrigal Pharmaceuticals expands MASH pipeline with global license agreement

PFE

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Jan 9, 2026, 8:00 AM EST - 5 months ago

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 4:05 PM EST - 6 months ago

Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Madrigal Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 1:30 PM EST - 6 months ago

Madrigal Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Madrigal Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 4:15 PM EST - 6 months ago

Madrigal Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Madrigal Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 20, 2025, 3:30 AM EST - 7 months ago

Madrigal Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Nov 17, 2025, 8:00 AM EST - 7 months ago

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis

Nov 10, 2025, 8:00 AM EST - 7 months ago

Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 7 months ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q3 2025

Madrigal Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 7 months ago

Madrigal Pharmaceuticals Quarterly report: Q3 2025

Madrigal Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 7 months ago

Madrigal Pharmaceuticals Earnings release: Q3 2025

Madrigal Pharmaceuticals Slides: Q3 2025

Nov 4, 2025, 8:00 AM EST - 7 months ago

Madrigal Pharmaceuticals Slides: Q3 2025

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates

Nov 4, 2025, 7:00 AM EST - 7 months ago

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 7 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MEDI

Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025

Oct 28, 2025, 8:00 AM EDT - 8 months ago

Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025

Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

Madrigal Pharma CEO talks competition in the liver disease treatment space

Oct 16, 2025, 6:18 PM EDT - 8 months ago

Madrigal Pharma CEO talks competition in the liver disease treatment space

Madrigal Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 7:45 AM EDT - 9 months ago

Madrigal Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Aug 19, 2025, 4:05 PM EDT - 10 months ago

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 10:30 AM EDT - 10 months ago

Madrigal Pharmaceuticals Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Madrigal Pharmaceuticals CEO: We're positioned for decades of growth

Aug 8, 2025, 6:15 PM EDT - 10 months ago

Madrigal Pharmaceuticals CEO: We're positioned for decades of growth

Madrigal Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q2 2025

Madrigal Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals Quarterly report: Q2 2025

Madrigal Pharmaceuticals Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals Earnings release: Q2 2025

Madrigal Pharmaceuticals Slides: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals Slides: Q2 2025

Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 7:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

Jul 30, 2025, 5:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

Jul 25, 2025, 8:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH

Jul 22, 2025, 8:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

Jul 16, 2025, 8:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval

Jun 20, 2025, 7:35 AM EDT - 1 year ago

Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Jun 20, 2025, 6:30 AM EDT - 1 year ago

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 10:40 AM EDT - 1 year ago

Madrigal Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

Madrigal Pharmaceuticals Transcript: Status Update

May 13, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Transcript: Status Update

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

May 10, 2025, 7:15 AM EDT - 1 year ago

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals Earnings Call Transcript: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q1 2025

Madrigal Pharmaceuticals Quarterly report: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Quarterly report: Q1 2025

Madrigal Pharmaceuticals Earnings release: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Earnings release: Q1 2025

Madrigal Pharmaceuticals Slides: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Slides: Q1 2025

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025, 7:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

Madrigal Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Proxy statement: Proxy Filing

Madrigal Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Proxy statement: Proxy Filing

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D.

Apr 16, 2025, 7:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D.

Madrigal Appoints Jacqualyn A. Fouse, Ph.D.

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Madrigal Appoints Jacqualyn A. Fouse, Ph.D.

Madrigal Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 11:10 AM EST - 1 year ago

Madrigal Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Madrigal CEO on Q4 earnings beat, MASH drug market opportunity

Feb 26, 2025, 6:33 PM EST - 1 year ago

Madrigal CEO on Q4 earnings beat, MASH drug market opportunity

Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2024

Madrigal Pharmaceuticals Annual report: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Annual report: Q4 2024

Madrigal Pharmaceuticals Earnings release: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Earnings release: Q4 2024

Madrigal Pharmaceuticals Slides: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Slides: Q4 2024

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Feb 26, 2025, 7:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Feb 26, 2025, 6:30 AM EST - 1 year ago

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Feb 21, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Feb 12, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Madrigal Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

Madrigal Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Madrigal Pharmaceuticals Slides: FY 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

Madrigal Pharmaceuticals Slides: FY 2025

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Jan 13, 2025, 6:45 AM EST - 1 year ago

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

Jan 8, 2025, 11:13 AM EST - 1 year ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MRK PFE

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Madrigal Pharmaceuticals Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 5, 2024, 8:30 AM EST - 1 year ago

Madrigal Pharmaceuticals Transcript: Piper Sandler 36th Annual Healthcare Conference

Madrigal Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 4, 2024, 9:35 AM EST - 1 year ago

Madrigal Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Conference

Madrigal Pharmaceuticals Transcript: UBS Global Healthcare Conference 2024

Nov 13, 2024, 2:00 PM EST - 1 year ago

Madrigal Pharmaceuticals Transcript: UBS Global Healthcare Conference 2024

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

Nov 6, 2024, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

Wallst45
Wallst45 Jun. 11 at 7:27 PM
$MDGL again sell off into close lol 😂
0 · Reply
Wallst45
Wallst45 Jun. 11 at 5:51 PM
$MDGL may be Madrigal signed NDA with the buyer ??
0 · Reply
Wallst45
Wallst45 Jun. 11 at 5:27 PM
$MDGL silent buyout announcement only ?
0 · Reply
sarkar20
sarkar20 Jun. 11 at 4:27 PM
$MDGL What is happening? Why Madrigal is not releasing good news!! 🤔🤔 I found below great news and it is not released or have not seen by me. So they are going into Middle east region too!! 🔥🔥
0 · Reply
Wallst45
Wallst45 Jun. 11 at 1:50 PM
$MDGL makes sense
0 · Reply
Wallst45
Wallst45 Jun. 11 at 12:47 PM
$MDGL looks like they are hanging in the price as talks continue ??
1 · Reply
Live2ride
Live2ride Jun. 11 at 11:55 AM
$MDGL Hope we catch a bid today. We are due.
0 · Reply
Wallst45
Wallst45 Jun. 10 at 6:01 PM
$MDGL volumes picking up today, what’s brewing??
1 · Reply
Live2ride
Live2ride Jun. 10 at 5:57 PM
$MDGL Can we get back to a 5 handle please?
0 · Reply
Wallst45
Wallst45 Jun. 10 at 4:24 PM
$MDGL going to be very profitable and no more BD, nice 👍🏼
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jun. 10 at 4:00 PM
$MDGL In 2026, we were very clear on the Q1 call that we do not expect to be profitable in 2026. Now, there may be quarters in the near term where we dip our toe into profitability, and then are not profitable.
1 · Reply
Wallst45
Wallst45 Jun. 10 at 3:48 PM
$MDGL this will get bought out soon. Just listen to Goldman Sachs conference
1 · Reply
Wallst45
Wallst45 Jun. 9 at 3:57 PM
$MDGL holding strong 💪🏼
0 · Reply
forprofit12
forprofit12 Jun. 9 at 11:50 AM
$MDGL 1 share traded for 441. We can relax for now
1 · Reply
Wallst45
Wallst45 Jun. 8 at 8:12 PM
$MDGL low volume push as usual
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jun. 8 at 7:45 PM
$MDGL WTF! They are just drilling this.
1 · Reply
Wallst45
Wallst45 Jun. 8 at 3:50 AM
$MDGL Great news for Madrigal ✅ 40% discontinuation rate is bad.
2 · Reply
Wallst45
Wallst45 Jun. 7 at 9:36 PM
$MDGL $ZEAL Survodutide - terrible molecule. Survodutide MASH drug poor performance and barely competitive with $MDGL Rezdiffra drug with major tolerability issues. Survodutide’s SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial https://x.com/wallstsai/status/2063726409340850247?s=46
0 · Reply
Wallst45
Wallst45 Jun. 5 at 7:17 PM
$MDGL why are we holding so strong despite market dump ??
2 · Reply
ReapN
ReapN Jun. 5 at 6:52 PM
$ALOY SP will ’most likely’ resemble other Monopolies. Example: $MDGL Mash/Nash mini-monopoly (for a few more years) REalloys monopoly will remain for Decades ’Golden Dome protected ZONE’ ’ WE the People Love GROWTH stock’ just speculating
0 · Reply
Wallst45
Wallst45 Jun. 5 at 1:08 PM
$MDGL starting Jun10th they can sell Rezdiffra in the UK. Great news 🗞️
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jun. 5 at 12:57 PM
$MDGL looks like it will not bring in any revenues in the near term until they address the cost and expense ownership.
0 · Reply